Innocan Pharma (INNPF) Return on Sales [ROS] (2024 - 2025)
Innocan Pharma's Return on Sales [ROS] came in at 31.84% for the quarter ended Dec 31, 2025, up 2.68 percentage points from 29.16% a year earlier and up 49.69 percentage points from the prior quarter.
Powered by 
Analysis
Innocan Pharma (INNPF) Return on Sales [ROS] (2024 - 2025) Analysis & Trends
For the year ended Dec 31, 2025, Innocan Pharma's Return on Sales [ROS] was 4.72%, up 0.48 percentage points from the prior year.
- Going back by year, Return on Sales [ROS] was 4.24% in the year ended Dec 31, 2024 (-23.61 pp) and 27.85% in the year ended Dec 31, 2023.
- The figure for the quarter ended Dec 31, 2025 represents the highest quarterly Return on Sales [ROS] in data going back to the quarter ended Mar 31, 2024.
- Year-over-year, Return on Sales [ROS] increased in two of the last four quarters, with an average year-over-year change of +1.10 percentage points.
- Business Quant data shows INNPF's Return on Sales [ROS] at -17.85% (quarter ended Sep 30, 2025), 5.65% (quarter ended Jun 30, 2025) and 6.27% (quarter ended Mar 31, 2025) in the three quarters before the quarter ended Dec 31, 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 32.98% |
| 10 | Innocan Pharma | 5.78 Mn | 1.73 Mn | 4.43 Mn | 31.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 31.84% |
| Sep 30, 2025 | -17.85% |
| Jun 30, 2025 | 5.65% |
| Mar 31, 2025 | 6.27% |
| Dec 31, 2024 | 29.16% |
| Sep 30, 2024 | 4.08% |
| Jun 30, 2024 | 6.15% |
| Mar 31, 2024 | -17.91% |
API Access
Innocan Pharma Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=INNPF&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "INNPF", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=INNPF&period=max&api_key=YOUR_API_KEY");
const data = await res.json();